mafosfamide has been researched along with fluorouracil in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Futami, H; Jansen, R; Keller, J; Longo, DL; MacPhee, MJ; McCormick, K; Oppenheim, JJ; Ruscetti, FW; Wiltrout, RH | 1 |
| Battaglia, M; Bertolini, F; Caprotti, M; Gibelli, N; Lanza, A; Palermo, B; Pavesi, L; Robustelli della Cuna, G | 1 |
| Huober, J; Mueck, AO; Seeger, H; Wallwiener, D | 1 |
3 other study(ies) available for mafosfamide and fluorouracil
| Article | Year |
|---|---|
Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Topics: Animals; Carcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; In Vitro Techniques; Interleukin-1; Kidney Neoplasms; Leukopenia; Lung; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neutropenia; Recombinant Proteins; Survival Analysis; Tumor Cells, Cultured | 1990 |
Multilineage long-term engraftment potential of drug-resistant hematopoietic progenitors.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Component Removal; Cells, Cultured; Cyclophosphamide; Drug Resistance; Fluorouracil; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Membrane Glycoproteins; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Phenotype; Receptors, Cell Surface; Stem Cell Factor; Transplantation Conditioning; X Chromosome | 1997 |
Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Epirubicin; Estradiol; Female; Fluorouracil; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |